Telix Pharmaceuticals (MEX:TLX1 N) Other Current Payables: MXN322 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:TLX1 N Telix Pharmaceuticals Ltd MEX:TLX1 N
57 GF Score
Price MXN302.55
GF Value MXN796.27
! 7 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Other Current Payables?

Telix Pharmaceuticals MEX:TLX1 N 57 Other Current Payables is MXN322 Mil as of Dec. 2025. GuruFocus rates MEX:TLX1 N with a GF Score™ of 57/100 and a GF Value™ of MXN796.27. The stock has 7 warning signs investors should review.

Telix Pharmaceuticals's Other Current Payables for the quarter that ended in Dec. 2025 was MXN322 Mil.

Telix Pharmaceuticals's quarterly Other Current Payables increased from Dec. 2024 (MXN85 Mil) to Jun. 2025 (MXN719 Mil) but then declined from Jun. 2025 (MXN719 Mil) to Dec. 2025 (MXN322 Mil).

Telix Pharmaceuticals's annual Other Current Payables declined from Dec. 2023 (MXN922 Mil) to Dec. 2024 (MXN85 Mil) but then increased from Dec. 2024 (MXN85 Mil) to Dec. 2025 (MXN322 Mil).

Telix Pharmaceuticals Other Current Payables Related Terms

Telix Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Other Current Payables Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.41 433.88 922.28 84.69 321.65

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 922.28 0.00 84.69 718.67 321.65
MEX:TLX1 N
57GF Score
Telix Pharmaceuticals Ltd MEX:TLX1 N
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of MXN322 Mil mean?
Telix Pharmaceuticals (MEX:TLX1 N) has a Other Current Payables of MXN322 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Other Current Payables too high?
Telix Pharmaceuticals' current Other Current Payables is MXN322 Mil. Overall, Telix Pharmaceuticals has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Other Current Payables compare to VRTX and REGN?
Telix Pharmaceuticals' Other Current Payables of MXN322 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Other Current Payables is MXN322 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Telix Pharmaceuticals (MEX:TLX1 N) has a current Other Current Payables of MXN322 Mil. The stock's GF Value™ is MXN796.27, compared to a current price of MXN302.55 — trading 62% below its estimated fair value. The current Other Current Payables is MXN322 Mil. Telix Pharmaceuticals' overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Telix Pharmaceuticals (MEX:TLX1 N), the current Other Current Payables is MXN322 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (MEX:TLX1 N) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of MXN302.55 is trading 62% below its estimated GF Value™ of MXN796.27.

Key valuation signals for MEX:TLX1 N:

  • Other Current Payables: MXN322 Mil
  • GF Value™: MXN796.27 vs. price of MXN302.55 (62% below fair value)
  • GF Score™: 57/100 with 7 warning signs

No single metric tells the full story. See the MEX:TLX1 N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
57GF Score

Get the complete analysis for MEX:TLX1 N

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN302.55
Price
MXN796.27
GF Value